Roohollah Mohseni

Roohollah Mohseni

Auto-generated profile, based on publicly available information

Roohollah Mohseni

Clinical Biochemistry Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2019 in Discover Nano
Verified
Journal Article
Open access
PDF file
RMRoohollah Mohseni
Roohollah Mohseni
ZAZahra ArabSadeghabadi
Zahra ArabSadeghabadi
NZNasrin Ziamajidi
Nasrin Ziamajidi
RARoghayeh Abbasalipourkabir
Roghayeh Abbasalipourkabir
ARAzam RezaeiFarimani
Azam RezaeiFarimani
In the current study, we developed resveratrol (RES)-loaded solid lipid nanoparticle (SLN-RES) in order to improve insulin resistance through the upregulation of SNARE protein complex in rats with type 2 diabetes. The SLN-RES characteristics include the following: the average size of 248 nm, the zeta potential of − 16.5 mV, and 79.9% RES entrapment efficiency. The release profile of SLN-RES showed an initial burst followed by a sustained release in natural condition. Infrared spectroscopy results revealed good incorporation of RES into core SLN. Spherical nanoparticle with less aggregation was observed under electronic microscopic examination. Oral administration of SLN-RES prevented weight loss and showed better hypoglycemic effect than RES. Serum oxidative stress status was restored to the normal level by SLN-RES. Furthermore, expression of synaptosomal-associated protein 23 (Snap23), syntaxin-4 (Stx4), and vesicle-associated membrane protein 2 (Vamp2) as the major elements of SNARE protein complex were reduced by SLN-RES more significantly than RES treatment in muscle tissue. However, SLN-RES has a similar effect to RES treatment in adipose tissue. Taken together, our results revealed SLN-RES could be a modern and interestingly therapeutic approach for the improvement of insulin resistance through targeting the expression of Snap23, Stx4, and Vamp2 in adipose and muscle tissues.

5 December 2022 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
RMRoohollah Mohseni
Roohollah Mohseni
MTMaryam Teimouri
Maryam Teimouri
MSMohsen Safaei
Mohsen Safaei
ZSZahra Arab Sadeghabadi
Zahra Arab Sadeghabadi

9 June 2020 in Journal of Drug Targeting
Verified
Journal Article
Closed access
RHRazieh Heidari
Razieh Heidari
NDNeda Gholamian Dehkordi
Neda Gholamian Dehkordi
RMRoohollah Mohseni
Roohollah Mohseni
MSMohsen Safaei
Mohsen Safaei
Breast cancer is one of the most prevalent and deadliest cancers among women in the world because of its aggressive behavior and inadequate response to conventional therapies. Cellular and gene therapies based on mesenchymal stem cells (MSCs) represent promising treatment strategies for multiple diseases, such as cancers. MSCs are multipotent adult stem cells with important features for cell therapy, such as tissue homing to injured sites, their differentiation potential, their capacity of secreting plenty of trophic factors, and low immunogenicity. The quite easy isolation of these cells from various types of tissues are associated with no ethical concern when dealing with fetal or embryonic stem cells. The MSCs exhibit both pro and anti-oncogenic properties. However, genetic engineering of MSCs and nanoparticles is being employed as a means to solve some of these problems and improve the antitumor properties of these cells. The tumor-homing ability of MSCs and their exosomes to tumor niches have made them as a promising vector for targeted delivery of therapeutic agents to tumors site. The present study investigated MSCs specifications, pro- and anti-oncogenic properties of MSCs in breast cancer, and reviewed targeted breast cancer therapy via engineered MSCs, likely as potent cellular vehicles.


5 November 2022 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
ZSZahra Arab Sadeghabadi
Zahra Arab Sadeghabadi
KSKeihan Ghatreh Samani
Keihan Ghatreh Samani
FYFatemeh Yaghubi
Fatemeh Yaghubi
RMRoohollah Mohseni
Roohollah Mohseni

19 January 2021 in Toxicological & Environmental Chemistry
Verified
Journal Article
Closed access
ZAZahra Abpeikar
Zahra Abpeikar
RMRoohollah Mohseni
Roohollah Mohseni
MSMohsen Safaei
Mohsen Safaei
The article presents a hypothesis on a co-delivery strategy to suppress or reduce infection caused by the COVID-19 virus. Co-delivery was illustrated in many diseases, and results showed that it produced a high therapeutic efficacy against disorders. We proposed an approach to suppress or reduce infection caused by the coronavirus disease 2019 via designing an intelligent nano-liposome loaded with interferon γ, interleukin 4 and small interfering RNA against vimentin. At the surface of this nanostructure, there is a matrix metallopeptidase3 substrate to provide a platform for the enzymatic function of matrix metallopeptidase3 to destroy the extracellular matrix, angiotensin-converting enzyme 2 blocker, and antibody against vimentin for targeting, trans-activator of transcription peptide, and polyethylene glycol. Due to the increasing application of nano-liposomes commercially as a drug-delivery system, it is important to consider this effective approach for the coronavirus disease 2019 treatment. Graphical Abstract